BENZIMIDAZOLE-2-PIPERAZINE HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, PREPARATION METHOD AND USE THEREOF
申请人:SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD
公开号:US20160159776A1
公开(公告)日:2016-06-09
The present invention relates to a class of benzimidazole-2-piperazine heterocyclic derivatives, a preparation method and medical use thereof. Specifically, the present invention relates to a new benzimidazole-2-piperazine heterocyclic derivative of general Formula (I), a preparation method, a pharmaceutical composition containing the same, and use thereof as a therapeutic agent and especially as a poly(ADP-ribose)polymerase (PARP) inhibitor.
申请人:SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD 상하이 휘룽 라이프 사이언스 & 테크놀로지 코., 엘티디(520160032257)
公开号:KR20160021845A
公开(公告)日:2016-02-26
본 발명은 벤조이미다졸-2-피페라진헤테로고리 유도체, 그 제조방법 및 그의 약학적 응용에 관한 것이다. 구체적으로, 본 발명은 화학식(I)로 표시되는 신규 벤조이미다졸-2-피페라진헤테로고리 유도체, 그 제조방법 및 이 유도체를 함유하는 약물 조성물 그리고 이의 치료제로서의, 특히 폴리(ADP-리보오스)중합효소(PARP) 억제제로서의 용도에 관한 것이다.
This is a patent related to a novel benzimidazole-2-piperazinyl heterocyclic derivative represented by the chemical formula (I), its preparation method, and its pharmaceutical applications. Specifically, the invention relates to a novel benzimidazole-2-piperazinyl heterocyclic derivative represented by the chemical formula (I), its preparation method, a pharmaceutical composition containing this derivative, and its use as a therapeutic agent, particularly as a poly(ADP-ribose) polymerase (PARP) inhibitor.
[EN] BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS<br/>[FR] BENZIMIDAZOLES ET ANALOGUES ASSOCIÉS EN TANT QUE MODULATEURS DE SIRTUINE
申请人:SIRTRIS PHARMACEUTICALS INC
公开号:WO2010003048A1
公开(公告)日:2010-01-07
Provided herein are sirtuin-modulating compounds of formula (II) The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.